labetalol has been researched along with Adverse Drug Event in 5 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Excerpt | Relevance | Reference |
---|---|---|
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Matthews, EJ | 1 |
Kruhlak, NL | 1 |
Weaver, JL | 1 |
Benz, RD | 1 |
Contrera, JF | 1 |
Chen, M | 1 |
Vijay, V | 1 |
Shi, Q | 2 |
Liu, Z | 2 |
Fang, H | 2 |
Tong, W | 2 |
Ding, D | 1 |
Kelly, R | 1 |
Sakatis, MZ | 1 |
Reese, MJ | 1 |
Harrell, AW | 1 |
Taylor, MA | 1 |
Baines, IA | 1 |
Chen, L | 1 |
Bloomer, JC | 1 |
Yang, EY | 1 |
Ellens, HM | 1 |
Ambroso, JL | 1 |
Lovatt, CA | 1 |
Ayrton, AD | 1 |
Clarke, SE | 1 |
Wu, CS | 1 |
Sung, SF | 1 |
Tong, SH | 1 |
Ong, CT | 1 |
5 other studies available for labetalol and Adverse Drug Event
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |